Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 6, 2011, Pages 1196-1203

  FitzGerald, Liesel M ^a   Kwon, Erika M ^b,c   Conomos, Matthew P ^a   Kolb, Suzanne ^a   Holt, Sarah K ^a   Levine, David ^a   Feng, Ziding ^a   Ostrander, Elaine A ^b   Stanford, Janet L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 3; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 79958029769     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-1299     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006;38:652-8. (Pubitemid 43927306)
3. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40:316-21. (Pubitemid 351311772)
4. Eeles RA, Kote-Jarai Z, Olama AA, Giles GG. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009;41:1116-21.
5. Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason A, Agnarsson BA, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009;41:1122-6.
6. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39:631-7. (Pubitemid 46676102)
7. Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A, Gudbjartsson D, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008;40:281-3. (Pubitemid 351311771)
8. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007;39:977-83. (Pubitemid 47185170)
9. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008;40:310-5. (Pubitemid 351311773)
10. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645-9. (Pubitemid 46676108)
11. Camp NJ, Farnham JM, Wong J, Christensen GB, Thomas A, Cannon-Albright LA. Replication of the 10q11 and Xp11 prostate cancer risk variants: results from a Utah pedigree-based study. Cancer Epidemiol Biomarkers Prev 2009;18:1290-4.
12. FitzGerald LM, Kwon EM, Koopmeiners JS, Salinas CA, Stanford JL. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Cancer Res 2009;15:3231-37.
13. Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 2008;17:2052-61.
14. Salinas CA, Kwon E, Carlson CS, Koopmeiners JS, Feng Z, Karyadi DM, et al. Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:1203-13.
15. Schumacher FR, Feigelson HS, Cox DG, Haiman CA, Albanes D, Buring J, et al. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res 2007;67:2951-6. (Pubitemid 46724830)
16. Severi G, Hayes VM, Padilla EJ, English DR, Southey MC, Sutherland RL, et al. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:610-2. (Pubitemid 46548668)
17. Sun J, Purcell L, Gao Z, Isaacs SD, Wiley KE. Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate 2008;68:691-7.
18. Suuriniemi M, Agalliu I, Schaid DJ, Johanneson B, McDonnell SK, Iwasaki L, et al. Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev 2007;16:809-14. (Pubitemid 46650586)
19. Wang L, McDonnell SK, Slusser JP, Hebbring SJ, Cunningham JM, Jacobsen SJ, et al. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res 2007;67:2944-50. (Pubitemid 46724829)
20. Waters KM, Le Marchand L, Kolonel LN, Monroe KR, Stram DO, Henderson BE, et al. Generalizability of associations from prostate cancer genome-wide association studies in multiple populations. Cancer Epidemiol Biomarkers Prev 2009;18:1285-9.
21. Xu J, Kibel AS, Hu JJ, Turner AR, Pruett K, Zheng SL, et al. Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev 2009;18:2145-9.
22. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008:910-19. (Pubitemid 351397090)
23. Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007;99:1836-44. (Pubitemid 351767196)
24. Sun J, Zheng SL, Wiklund F, Isaacs SD, Li G, Wiley KE, et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res 2009;69:10-5.
25. Xu J, Zheng SL, Isaacs SD, Wiley KE, Wiklund F, Sun J, et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A 2010;107:2136-40.
26. Chang BL, Isaacs SD, Wiley KE, Gillanders EM, Zheng SL. Genomewide screen for prostate cancer susceptiblity genes in men with clinically significant disease. Prostate 2005;64:365-661.
27. Schaid DJ, McDonnell SK, Zarfas KE, Cunningham JM, Hebbring S, Thibodeau SN, et al. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet 2006;120:471-85. (Pubitemid 44669782)
28. Schaid DJ, Stanford JL, McDonnell SK, Suuriniemi M, McIntosh L, Karyadi DM, et al. Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q. Hum Genet 2007;121:729-35. (Pubitemid 46916972)
29. Slager SL, Zarfas KE, Brown WM, Lange EM, McDonnell SK. Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan prostate cancer genetics project. Prostate 2006;66:173-9.
30. Stanford JL, McDonnell SK, Friedrichsen DM, Carlson EE, Kolb S, Deutsch K, et al. Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness. Prostate 2006;66:317-25.
31. Witte JS, Goddard KA, Conti DV, Elston RC, Lin J, Suarez BK, et al. Genome-wide scan for prostate cancer-aggressiveness loci. Am J Hum Genet 2000;67:92-9. (Pubitemid 30481547)
32. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008;168:250-60. (Pubitemid 352019786)
33. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK. Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999;8:881-6. (Pubitemid 29508723)
34. Laurie CC, Doheny KF, Mirel DB, Pugh EW, Bierut LJ, Bhangale T, et al. Quality control and quality assurance in genotypic data for genome-wide association studies. Genet Epidemiol 2010;34:591-602.
35. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet 2006;2:e190.
36. The National Cancer Institute Cancer Genetic Markers of Susceptibility (CGEMS) project. 2005; Available from: http://cgems.cancer.gov/
37. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
38. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
39. Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, et al. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 2009;69:1195-205.
40. Wiklund FE, Adami HO, Zheng SL, Stattin P, Isaacs WB, Gronberg H, et al. Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev 2009;18:1659-62.
41. Kraft P, Hunter DJ. Genetic risk prediction - are we there yet? N Engl J Med 2009;360:1701-3.
42. Roehl KA, Han M, Ramos CG, Antenor JV, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910-4. (Pubitemid 39096421)
43. Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol 2009;182:2702-7.
44. Kayser M, Liu F, Janssens AC, Rivadeneira F, Lao O, van Duijn K, et al. Three genome-wide association studies and a linkage analysis identify HERC2 as a human iris color gene. Am J Hum Genet 2008;82:411-23.
45. Sturm RA, Duffy DL, Zhao ZZ, Leite FP, StarkMS, Hayward NK, et al. A single SNP in an evolutionary conserved region within intron 86 of the HERC2 gene determines human blue-brown eye color. Am J Hum Genet 2008;82:424-31.
46. Bekker-Jensen S, Rendtlew Danielsen J, Fugger K, Gromova I, Nerstedt A, Lukas C, et al. HERC2 coordinates ubiquitin-dependent assembly of DNA repair factors on damaged chromosomes. Nat Cell Biol 2010;12:80-6.
47. Kang TH, Lindsey-Boltz LA, Reardon JT, Sancar A. Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. Proc Natl Acad Sci U S A 2010;107:4890-5.
48. Wu W, Sato K, Koike A, Nishikawa H, Koizumi H, Venkitaraman AR, et al. HERC2 is an E3 ligase that targets BRCA1 for degradation. Cancer Res 2010;70:6384-92.
49. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8. (Pubitemid 28406815)
50. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 2006;38:209-13. (Pubitemid 43177235)